OverviewSuggest Edit
Oncopeptides is a clinical development pharmaceutical company. It develops anti-cancer drugs. The Company has created Ygalo, a cytotoxic therapy that is in late-stage development use for the treatment of multiple myeloma.
| Type | Public | |
| Founded | 2000 | |
| HQ | Stockholm, SE | Map |
| Website | oncopeptides.com |
Key People/Management at Oncopeptides
Brian Stuglik
Director
Marty J Duvall
Chief Executive Officer
Cecilia Daun Wennborg
Director
Paula Boultbee
Chief Commercial Officer
Jarl Ulf Jungnelius
Director
Eva Nordström
Vice President, Chief Operating Officer
Oncopeptides Office Locations
Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham
Stockholm, SE (HQ)
46 Luntmakargatan
Stockholm, SE
Tändstickspalatset, Västra Trädgårdsgatan 15
Los Altos, CA, US
4940 El Camino Real #100
Mountain View, CA, US
444 Castro St
Waltham, MA, US
200 5th Ave #1030
Oncopeptides Financials and Metrics
Oncopeptides Revenue
Oncopeptides's revenue was reported to be kr118.3 m in FY, 2021
| SEK | |
|---|---|
Revenue (FY, 2021) | 118.3m |
Gross profit (FY, 2021) | 132.8m |
Net income (FY, 2021) | (1.4b) |
EBITDA (FY, 2021) | (1.4b) |
EBIT (FY, 2021) | (1.4b) |
Market capitalization (12-May-2022) | 627.2m |
Closing stock price (12-May-2022) | 8.3 |
Cash (31-Dec-2021) | 362.2m |
EV | 265.0m |
Oncopeptides's current market capitalization is kr627.2 m.
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Revenue | 118.3m | |||
Cost of goods sold | (53.1m) | |||
Gross profit | 10.1m | 8.3m | 132.8m | |
R&D expense | (313.5m) | (546.1m) | (860.9m) | (679.9m) |
Quarterly
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 19.4m | 66.4m | 54.3m | ||||||
Cost of goods sold | (328.0k) | (2.8m) | (31.6m) | ||||||
Gross profit | 2.2m | 3.3m | 16.1m | 8.3m | (8.3m) | 57.0m | 67.7m | 12.2m | |
R&D expense | (94.9m) | (144.4m) | (152.0m) | (213.5m) | (227.8m) | (193.4m) | (178.5m) | (167.3m) | (149.8m) |
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Cash | 375.6m | 926.2m | 840.3m | 362.2m |
Accounts Receivable | 11.9m | |||
Prepaid Expenses | 14.7m | 44.0m | 32.3m | 12.2m |
Inventories | 8.7m |
Quarterly
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 747.5m | 626.8m | 1.1b | 617.8m | 937.8m | 1.3b | 372.5m | 999.4m | 671.3m |
Accounts Receivable | 21.4m | 72.8m | 72.9m | ||||||
Prepaid Expenses | 78.3m | 17.8m | 7.0m | 6.5m | 6.2m | 102.4m | 26.6m | 25.5m | |
Inventories | 11.6m | 22.2m |
Annual
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|
Net Income | (411.0m) | (739.4m) | (1.6b) | (1.4b) |
Depreciation and Amortization | 345.0k | 4.5m | 2.0m | |
Inventories | (429.0k) | |||
Accounts Payable | 9.6m | 55.7m | 55.1m |
Quarterly
| SEK | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (121.9m) | (305.6m) | (495.1m) | (296.9m) | (696.2m) | (1.1b) | (347.3m) | (692.2m) | (1.0b) |
Oncopeptides Revenue Breakdown
Oncopeptides revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED
Oncopeptides Cybersecurity Score
Oncopeptides Environment, Social & Governance (ESG) Ratings
Oncopeptides Online and Social Media Presence
Oncopeptides's Trends
Oncopeptides News and Updates
April 21, 2022
Oncopeptides publishes the 2021 Annual Report
STOCKHOLM, April 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the 2021 Annual Report has been published. The Annual...
February 17, 2022
Oncopeptides publishes year-end report 2021
STOCKHOLM, Feb. 17, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021. Financial overview October-December Net sales...
February 17, 2022
Oncopeptides publishes year-end report 2021
STOCKHOLM, Feb. 17, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the year-end report 2021. Financial overview October-December Net sales...
January 13, 2022
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
STOCKHOLM, Jan. 13, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the data from the randomized head-to-head phase 3 OCEAN study,...
December 10, 2021
Oncopeptides presents new melflufen data at the Annual American Society of Hematology Meeting ASH
STOCKHOLM, Dec. 10, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company will present three posters on melflufen (INN...
November 24, 2021
Oncopeptides publishes Q3 2021 report
STOCKHOLM, Nov. 24, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today published the report for the third quarter 2021. Financial overview...
Oncopeptides Blogs
January 18, 2021
ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.
December 21, 2020
Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma
STOCKHOLM — December 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab co…
December 15, 2020
Oncopeptides strengthens its organization by appointing Linda Holmström as Director of Investor Relations
STOCKHOLM — December 15, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announced that Linda Holmström has been appointed Director of Investor Relations. Linda has mo…
December 09, 2020
Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology
STOCKHOLM — December 9, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating intravenous melflufen (INN melpha…
December 07, 2020
Oncopeptides will host a webcast on Wednesday, December 9 at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting
STOCKHOLM — December 7, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today announces that the company will host a webcast on Wednesday, December 9[th], 2020, at 14:00 (C…
November 19, 2020
INTERIM REPORT Q3 2020
Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189.8) Loss per share, before and after dilution, was SEK 5.71 (loss: 3.53) On September 30 cash and cash equivalents amounted to SEK 1,251.6 M (1,122.3) Significan…
Oncopeptides Frequently Asked Questions
When was Oncopeptides founded?
Oncopeptides was founded in 2000.
Who are Oncopeptides key executives?
Oncopeptides's key executives are Brian Stuglik, Marty J Duvall and Cecilia Daun Wennborg.
How many employees does Oncopeptides have?
Oncopeptides has 321 employees.
What is Oncopeptides revenue?
Latest Oncopeptides annual revenue is kr118.3 m.
What is Oncopeptides revenue per employee?
Latest Oncopeptides revenue per employee is kr368.5 k.
Who are Oncopeptides competitors?
Competitors of Oncopeptides include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.
Where is Oncopeptides headquarters?
Oncopeptides headquarters is located at 46 Luntmakargatan, Stockholm.
Where are Oncopeptides offices?
Oncopeptides has offices in Stockholm, Los Altos, Mountain View and Waltham.
How many offices does Oncopeptides have?
Oncopeptides has 5 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies